Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NALIRIFOX Perioperative Treatment in High-Risk Resectable Pancreatic Cancer
NCT06210360Phase 2Not yet recruiting
- Sponsor
- Changhai Hospital
- Start
- Feb 2024
- Primary completion
- Apr 2025
- Modality
- Lipid-based Nanoparticles, Small Molecules
01
Overview
A Phase 2 trial of irinotecan liposome injection in pancreatic ductal adenocarcinoma (PDAC), sponsored by Changhai Hospital. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
irinotecan liposome injection
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06210360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06210360.